We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-2.77%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.85B
AUM Growth
+$375M
(+8.4%)
Cap. Flow
-$1.26B
Cap. Flow
% of AUM
-25.93%
Top 10 Holdings %
Top 10 Hldgs %
37.89%
Holding
140
New
14
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$50.2M |
| 2 |
Gilead Sciences
GILD
|
+$48.7M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$32.8M |
| 4 |
MRUS
Merus
MRUS
|
+$32.3M |
| 5 |
Glaukos
GKOS
|
+$31.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$25.7M |
| 2 |
Organogenesis Holdings
ORGO
|
+$24.7M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$22.2M |
| 4 |
GoodRx Holdings
GDRX
|
+$18.9M |
| 5 |
Nuvation Bio
NUVB
|
+$18.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.31% |
| 2 | Financials | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
101
CALL
Glaukos
GKOS
$9.13B
| – | – |
-45,200
| Closed | -$2.61M |
|
|
KALV
102
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-830,472
| Closed | -$12.2M |
|
|
103
Nuvation Bio
NUVB
$2.18B
| – | – |
-3,577,233
| Closed | -$18.8M |
|
104
PMV Pharmaceuticals
PMVP
$68.3M
| – | – |
-470
| Closed | -$10K |
|
|
SWTX
105
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-249,988
| Closed | -$14.1M |
|
|
TERN
106
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-2,345,959
| Closed | -$6.97M |
|
|
VINC
107
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| – | – |
-68,966
| Closed | -$5.52M |
|
|
MRTX
108
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-270,000
| Closed | -$22.2M |
|
|
MTACU
109
DELISTED
MedTech Acquisition Corporation Unit
MTACU
| $0 | ﹤0.01% |
1
| – | – |
|
|
EUCRU
110
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
| $0 | ﹤0.01% |
1
| – | – |
|
|
SRSAU
111
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
| $0 | ﹤0.01% |
1
| – | – |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q2 2022 Portfolio in Review
As of Q2 2022, Deerfield Management held 140 positions worth $4.85B, up 8.4% from $4.47B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Deerfield Management withdrew a net $1.26B in Q2 2022, closing 14 positions and reducing 12 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $22.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in HilleVax worth $28.6M.
- Deerfield Management's largest Q2 2022 buy was HilleVax: 2,617,948 shares worth $28.6M.
- Deerfield Management added most to Immunogen Inc in Q2 2022, an estimated $50.2M increase.
- Deerfield Management's biggest Q2 2022 reduction was Kura Oncology, cutting an estimated $25.7M.
- Deerfield Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $22.2M.
- Deerfield Management's ten largest holdings make up 38% of its $4.85B portfolio in Q2 2022.
- Deerfield Management opened 14 new positions and closed 14 in Q2 2022.
- Deerfield Management's portfolio value rose 8.4% quarter-over-quarter to $4.85B.
Based on Deerfield Management's 13F filing for Q2 2022, filed 15 Aug 2022.